FibroGen shares are trading lower. The company announced topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in patients with pancreatic cancer and said its Precision Promise study in metastatic pancreatic cancer did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
FibroGen shares are trading lower after the company announced that its two late-stage trials for pamrevlumab in pancreatic cancer did not meet the primary endpoint.
July 31, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
FibroGen's late-stage trials for pamrevlumab in pancreatic cancer did not meet the primary endpoint, leading to a decline in share price.
The failure to meet the primary endpoint in late-stage trials is a significant setback for FibroGen, likely leading to a negative impact on the stock price due to reduced investor confidence and potential future revenue loss.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100